
Full profile: /officials/C001056
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-07-17
Source: Congress.gov
Currently in
Previously
Halting the Epidemic of Addiction and Loss Act of 2025 This bill requires that, when the Department of Health and Human Services (HHS) issues new regulations or guidance on grant programs addressing opioid use disorders, references to an opioid overdose reversal drug (e.g., naloxone) must broadly include any opioid overdose reversal drug approved by the Food and Drug Administration. Within one year after the bill’s enactment, HHS must update all references accordingly in regulations or guidance issued prior to the bill’s enactment that are applicable to State Opioid Response Grants, Tribal Opioid Response Grants, or certain other grants relating to substance use disorder prevention.
Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.
Bills by the same sponsor or covering overlapping subjects.